Dr Lueff completed his studies at Semmelweis Medical University between 1986 and 1992.
Between 1992 and 1997, he worked at the Budapest Municipality St László Hospital, before beginning work at the Hungarian National Hematology and Blood Transfusion Institute in 2000. Dr Lueff completed his professional training at the St László Hospital, the Hematology and Blood Tranfusion Institute of the Haynal Imre University of Health Sciences and the Royal Free Hospital in London. He began working in St László Hospital in 2000, before working at the Haynal Imre University of Health Sciences and the Budapest Municipality St István and St László Hospitals, firstly as chief physician and then from 2010 as chief physician and department head.
In 2004, he gained professional experience at the Royal Free Hospital in London, before managing the Budapest Municipal Cytogenetics and FISH Laboratory alongside his clinical work.
Starting in 2002, he worked closely with the Gottsegen György Hungarian National Institute of Cardiology in a clinical research program, part of which examined stem cell treatment following heart attacks, as well as ad hoc professional consultation work.
Since 2012, he has worked in the UK as a hematologist consultant.
He is a General Medical Council (GMC) registered hematologist. He is a member of the Royal College of Pathologists.
He was previously a member of the Nottingham University Hospital Multi-Disciplinary Team, and from 2013 to 2018 he was a permanent member of the Sheffield Hallamshire University Hospital Multi-Disciplinary Team. At the Chesterfield Royal Hospital NHS Foundation Trust he was the myeloid diseases supervisor and the Trust's professional transfusion supervisor, while he also took part in training for students of the Sheffield/Hallam University Medical School and post-graduate training.
He specializes in myeloid, lymphoid, myeloma and general hematology clinical care, and continues to work for the NHS in the UK. He worked for four years in a multi-disciplinary deep vein thrombosis / lung embolism clinic with consultants from the Sheffield University Hospital Pulmonaris Hypertonia group.
Clinical tests: Dr Lueff was also was the chief investigator of British national studies of acute myeloid leukemia (AML 17, AML18, AML19) at the Chesterfield Royal Hospital NHS Foundation Trust.
He was also the chief clinical investigator for the SPIRIT 2 trials examining the use of Dasatinib to treat sufferers of chronic myeloid leukemia, as well as the chief investigator of British registration for patients with myelodysplasia at the CRH NHS Foundation Trust.
He is currently working in a hematology clinic for the British National Health Service, in the hematology department and as a hematology consultant in laboratories.